Eikon Therapeutics has raised $381 million from its IPO, at the top end of its expectations, in another sign of a pickup in appetite for new biotech listings on the Nasdaq. The South San Francisco ...

All the Latest Game Footage and Images from Farewell, Eikon Sleeping on the job, running out of ice cream, and being locked out of his hometown due to a storm. Things just can’t seem to go right for ...

Investing.com -- Eikon Therapeutics Inc. (NASDAQ:EIKN) shares fell 5.7% following Wedbush analyst Robert Driscoll’s initiation of coverage with an Underperform rating and a $7.00 price target. The ...

Investing.com - Wedbush initiated coverage on Eikon Therapeutics Inc. (NASDAQ:EIKN) with an Underperform rating and set a price target of $7.00, the firm said Wednesday. The target implies more than ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon Therapeutics increased the ...

Feb 5 (Reuters) - Drug developer Eikon Therapeutics , headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.3% below their offer price in their Nasdaq ...

Despite progress made in cancer immunotherapy, some patients don’t respond to these treatments or they stop responding after a period of time. Eikon Therapeutics’ lead drug candidate could address ...

Eikon Therapeutics, Inc. (Nasdaq: EIKN), a California-based, late-stage biotechnology company, visits the Nasdaq MarketSite in Times Square. Eikon is led by executive and clinical teams behind the ...

Shares of Eikon Therapeutics are set to begin trading Thursday after the clinical-stage biopharmaceutical company's upsized initial public offering was priced at the top of expectations. Eikon late ...

Eikon Therapeutics raised an upsized US$381m late Wednesday from its Nasdaq IPO that included participation by Merck, a banker involved in the offering told IFR. The banks were multiple times ...